Lateral Flow Assay Design: Components and Principles

Lateral flow assays are paper-based diagnostic devices that detect the presence or absence of an analyte in a liquid sample through capillary flow across sequential functional zones. A typical strip contains a sample pad, conjugate pad, nitrocellulose membrane, and absorbent pad, each performing a distinct role in generating a visible signal. This article explains the function of each component, the design decisions that determine assay performance, and a practical checklist for developing a new lateral flow assay in a laboratory setting.

Lateral flow assays are quick, simple, and inexpensive tools for analyzing samples at the point of care or in the field, which makes them one of the most widely used biosensor formats currently available [8]. They have been applied to detect targets ranging from atoms to whole cells in water, blood, food, and environmental samples [8]. The operation relies on capillary flow of the sample through a series of sequential pads, each with different functionalities that work together to generate a signal indicating the absence or presence, and in some cases the concentration, of the analyte of interest [8].

The performance, field utility, and low cost of lateral flow assays have driven a tremendous shift in global health care practices by enabling diagnostic testing in previously unserved settings [6]. This success has motivated continued improvement through increasingly sophisticated materials and reagents, yet the mechanistic understanding of the underlying processes that inform design has not received commensurate attention [6]. Computational modeling integrated with lateral flow development offers a framework for choosing among novel materials, techniques, and reagents to deliver low-cost, high-fidelity assays [6].

At a Glance

The table below summarizes the primary components of a lateral flow strip, their functions, and key design considerations for each.

Core Principles of Lateral Flow Assay Operation

Capillary Flow and Sequential Pad Function

The lateral flow assay operates on the principle of capillary flow, where a liquid sample migrates through a series of porous materials by wicking action [8]. The sample is applied to the sample pad, then moves into the conjugate pad where it rehydrates dried detection reagents. The mixture continues across the nitrocellulose membrane where capture reagents are immobilized at defined locations, and finally into the absorbent pad that maintains the flow [8].

Each pad in the sequence has a specific function. The sample pad conditions the sample and removes particulates. The conjugate pad stores the labeled detection reagent in a dry form that must release efficiently when rehydrated. The membrane provides the surface where the analytical reaction occurs and where the signal is generated. The absorbent pad acts as a pump that draws the liquid through the system [8].

Signal Generation Mechanisms

The most common lateral flow format is the sandwich assay, where the analyte is captured between two antibodies or other binding reagents. One binding reagent is conjugated to a detectable label, typically gold nanoparticles, and the other is immobilized on the membrane at the test line. When the analyte is present, it forms a bridge between the labeled and immobilized reagents, producing a visible line [8].

Competitive formats are used for small molecules that cannot simultaneously bind two antibodies. In these assays, the analyte competes with a immobilized analyte analog for binding to the labeled reagent. The presence of the analyte reduces or eliminates the signal at the test line [14]. Traditional competitive small molecule lateral flow assays have inherent sensitivity limitations, which has motivated the development of alternative approaches such as de novo designed proteins that can sandwich a small molecule between two binding domains [14].

Nucleic acid lateral flow assays operate on hybridization principles instead of antibody-antigen interactions. A target nucleic acid sequence is amplified, often by isothermal methods, and the amplicons are detected by hybridization to labeled probes and capture probes immobilized on the membrane [11]. Gold nanoparticles are commonly employed to enable visual detection in these formats [11].

Membrane Selection and Properties

Nitrocellulose Membrane Characteristics

The nitrocellulose membrane is the most critical component of a lateral flow strip because it determines the flow characteristics and provides the surface for reagent immobilization. Membrane pore size affects flow rate, which in turn influences the time available for binding reactions and the sensitivity of the assay [8].

Membrane selection requires consideration of the balance between flow rate and sensitivity. Faster flow rates reduce assay time but provide less time for the analyte to bind to capture reagents, which can decrease sensitivity. Slower flow rates increase binding time but prolong the assay and may increase nonspecific binding [8].

Different membrane types can perform similarly in nucleic acid lateral flow assays. A study evaluating two membrane types for detection of a conserved viral gene region found no significant differences in performance between the membranes across all probe concentrations tested [11]. This finding suggests that membrane selection may be less critical for some nucleic acid formats than for protein-based assays, but it does not eliminate the need for empirical testing [11].

Flow Rate and Pore Size Considerations

The micropores within membrane and conjugate pad components impose resistance to the flow of sample solution, which reduces flow velocity and prolongs detection time [16]. Conventional lateral flow strips are composed of laminated porous components, and the micropores within these components create resistance that slows the sample migration [16].

Integrated fabrication approaches can address flow limitations. A unidirectional-flow assay strip fabricated via an integrated process produced all components on a barbed-arrow structure membrane, providing a straight flow path and maintaining flow continuity [16]. This design achieved a solution utilization of 35.7 percent, supporting detection with small-volume samples [16].

Membrane Lot Consistency

Membrane properties can vary between manufacturing lots, which affects assay reproducibility. Nitrocellulose membranes differ in protein binding capacity, flow rate, and background signal characteristics. When developing a lateral flow assay, it is important to evaluate multiple membrane lots and establish acceptance criteria for each lot before committing to large-scale production [8].

Conjugate Pad and Label Selection

Function of the Conjugate Pad

The conjugate pad stores the detection reagent in a dry form that must be released efficiently when the sample flows through. The pad material, the composition of the drying buffer, and the loading density all affect the release efficiency and therefore the assay sensitivity [8].

The conjugate pad must release the labeled reagent completely and consistently. Incomplete release reduces the amount of labeled reagent available for binding, which decreases signal intensity and can cause false negative results. The drying process must preserve the activity of the biological reagent, whether it is an antibody, aptamer, or nucleic acid probe [8].

Gold Nanoparticle Labels

Gold nanoparticles are the most commonly used label in lateral flow assays because they produce a visible red signal without additional development steps [11]. The nanoparticles are conjugated to antibodies, aptamers, or nucleic acid probes, and the conjugate must remain stable during storage and release efficiently from the conjugate pad [8].

The size and quality of gold nanoparticles affect assay performance. Larger nanoparticles produce stronger signals but may be less stable and more prone to aggregation. The conjugation chemistry must be optimized to ensure that the biological reagent is attached in the correct orientation and density [8].

Alternative Labels and Detection Methods

Fluorescent labels such as quantum dots and europium chelate-doped nanoparticles offer higher sensitivity than gold nanoparticles but require a reader device for signal detection [14]. Quantum dots conjugated to streptavidin have been used in lateral flow assays for small molecule detection, but they perform poorly in undiluted human serum due to perturbation of the zinc sulfide shell by serum components [14]. Europium chelate-doped polystyrene nanoparticles preserve the long Stokes shift advantage while protecting the fluorophore from serum-induced quenching [14].

Surface-enhanced Raman scattering labels provide another approach for sensitive detection. A CRISPR/Cas13a-driven lateral flow biosensor using surface-enhanced Raman scattering and colorimetric dual-signal detection achieved a limit of detection of 8.96 attomolar by surface-enhanced Raman scattering and 1 femtomolar by visualization [9]. This platform demonstrated the potential to meet requirements for both convenient point-of-care visual detection and more accurate sensitive detection [9].

Aptamer-Based Recognition

Aptamers offer an alternative to antibodies as recognition elements in lateral flow assays. Aptamers have strong affinity toward their targets, including small, large, and non-immunogenic molecules, because of their high affinity, sensitivity, low dissociation constant, cost-effectiveness, and flexible nature [23]. Aptamer-based lateral flow assays can overcome limitations of antibodies such as tedious in vivo processes, short shelf-life, and functionalization issues [23].

The design of aptamer-based lateral flow assays for small molecules typically relies on target-induced dissociation competitive binding among the aptamer, target, and gold nanoparticle-complementary DNA nanoprobes [12]. The nanoprobe design has a strong effect on the sensitivity and specificity of the assay [12]. Systematic optimization of the hybridization site and length of the complementary DNA fragment with the aptamer is required to achieve optimal performance [12].

Capture Reagent Immobilization

Test Line and Control Line Placement

Capture reagents are immobilized on the nitrocellulose membrane at defined locations to form the test line and control line. The test line captures the analyte-labeled complex, while the control line confirms that the liquid flowed through the strip and that the detection reagents functioned correctly [8].

The control line is essential for assay validity. A visible control line indicates that the sample migrated through the membrane and that the labeled reagent was released from the conjugate pad. If the control line does not appear, the test result is invalid regardless of the test line signal [8].

Immobilization Methods

Capture reagents can be immobilized on the membrane by direct adsorption or through affinity interactions. Direct adsorption relies on the hydrophobic and electrostatic interactions between the protein or nucleic acid and the nitrocellulose surface. Affinity-based immobilization uses a capture molecule such as streptavidin to bind a biotinylated reagent [15].

The choice of immobilization method affects assay performance and stability. Direct adsorption is simple but may result in variable orientation of the capture reagent. Affinity-based methods provide more controlled orientation but require additional reagents and optimization [15].

Biotin-Streptavidin Systems

Biotin-streptavidin interactions are widely used in lateral flow assay design for both immobilization and signal generation. However, the use of multiple biotinylated molecules can lead to assay failure due to competitive binding and steric hindrance [15]. A study developing a CRISPR-dCas9-based lateral flow assay for human papillomavirus detection found that excess biotin on both the dCas9-sgRNA complex and the PCR amplicons led to competition for streptavidin binding sites, improper binding configurations, disrupted protein folding, and interference with biotin-streptavidin interactions [15].

The study concluded that using multiple biotinylated molecules in CRISPR-dCas9-based lateral flow assays can cause assay failure and advocated the use of two different molecules for immobilization and signal generation [15]. Independent optimization of binding and reporting components is necessary to establish a functional assay platform [15].

Sample Pad and Sample Preparation

Sample Pad Function

The sample pad receives the applied sample and transports it to the conjugate pad. The pad material must be compatible with the sample type, whether it is whole blood, serum, plasma, urine, saliva, or an environmental sample [8]. The sample pad may contain buffers and reagents that condition the sample for optimal interaction with the detection reagents [8].

Sample pad selection affects assay performance through its influence on sample flow and reagent release. The pad must absorb the sample volume without retaining the analyte or the labeled reagents. The pad material and any pretreatment affect the pH and ionic strength of the sample as it enters the conjugate pad [8].

Sample Types and Compatibility

Lateral flow assays have been developed for a wide range of sample types, including water, blood, foodstuff, and environmental samples [8]. The sample matrix can affect assay performance through nonspecific binding, interference with the detection reaction, or physical properties such as viscosity and particulate content [8].

Saliva and serum present different challenges for lateral flow assay design. A cortisol lateral flow assay using quantum dots performed poorly in undiluted human serum, consistent with prior reports of zinc sulfide shell perturbation by serum components [14]. Substituting europium chelate-doped polystyrene nanoparticles protected the fluorophore from serum-induced quenching and enabled detection in pooled human serum [14].

Sample Preparation Requirements

Some lateral flow assays require sample preparation steps before the sample is applied to the strip. Nucleic acid lateral flow assays typically require amplification of the target sequence before detection [11]. Isothermal amplification methods such as recombinase-aided amplification can be performed at constant temperature and combined with lateral flow detection [20].

The total process time for nucleic acid lateral flow assays includes both the amplification and detection steps. A CRISPR/Cas13a-driven lateral flow biosensor for microRNA detection achieved a readout time of 10 minutes and a total process time of less than 45 minutes without the need for nucleic acid preamplification [9]. A duplex recombinase-aided amplification lateral flow dipstick assay for distinguishing Mycobacterium tuberculosis and Mycobacterium avium complex allowed effective amplification at constant 37 degrees Celsius within 20 minutes, with amplification products visually observed on the test strip [20].

Assay Formats and Detection Strategies

Sandwich Format

The sandwich format is used for analytes with sufficient size to bind two antibodies or other binding reagents simultaneously. The analyte is captured between a labeled detection reagent and an immobilized capture reagent, producing a signal that increases with analyte concentration [8].

Sandwich assays are commonly used for protein biomarkers, pathogens, and other large analytes. The sensitivity of the sandwich format depends on the affinity of the binding reagents, the label type, and the flow characteristics of the membrane [8].

Competitive Format

The competitive format is used for small molecules that cannot simultaneously bind two antibodies. In this format, the analyte competes with an immobilized analyte analog for binding to a limited amount of labeled reagent. The presence of the analyte reduces the signal at the test line [14].

Traditional competitive small molecule lateral flow assays have inherent sensitivity limitations [14]. De novo designed proteins that can sandwich a small molecule between two engineered binding domains offer an alternative that eliminates these limitations [14]. A cortisol-induced dimerization protein pair was used to develop the first lateral flow sandwich fluorescence assay for the small molecule hormone cortisol [14].

Nucleic Acid Detection Formats

Nucleic acid lateral flow assays detect amplified target sequences through hybridization to labeled probes and capture probes immobilized on the membrane [11]. The target sequence is typically amplified by polymerase chain reaction or isothermal amplification methods before detection [11].

Isothermal amplification methods are particularly suited for point-of-care applications because they do not require thermal cycling equipment. Recombinase-aided amplification operates at constant temperature and can be combined with lateral flow detection [20]. Loop-mediated isothermal amplification has been widely integrated with CRISPR-based detection systems for point-of-care diagnostics [22].

CRISPR-based detection systems use the collateral cleavage activity of Cas enzymes to generate detectable signals. Cas13a-mediated collateral RNase activity triggers the cleavage of labeled reporter molecules to produce detectable signals [19]. The combination of isothermal amplification with CRISPR detection and lateral flow readout offers a pathway for deployable nucleic acid diagnostics [17].

Multiplex Detection

Multiplex lateral flow assays detect multiple analytes simultaneously by incorporating multiple test lines on a single membrane. Each test line contains a capture reagent specific for a different analyte [16].

A unidirectional-flow assay strip developed for multiplex detection of serum amyloid A and C-reactive protein achieved detection within 7 minutes with detection limits of 0.254 micrograms per milliliter and 0.285 micrograms per milliliter, respectively [16]. In the detection of 26 clinical samples, this method showed a sensitivity of 93.8 percent and a specificity of 90.0 percent [16].

A duplex recombinase-aided amplification lateral flow dipstick assay was developed to distinguish Mycobacterium tuberculosis and Mycobacterium avium complex in a single test [20]. The assay showed high specificity with no cross-reactivity against other mycobacterial species and common respiratory pathogens, and demonstrated a detection limit as low as 10 squared colony-forming units per milliliter [20].

Design Considerations for Assay Development

Reagent Selection and Optimization

The selection of binding reagents is the most important decision in lateral flow assay development. Antibodies, aptamers, and nucleic acid probes each have advantages and limitations for different applications [8]. The binding affinity and specificity of the reagents determine the analytical sensitivity and specificity of the assay [8].

Monoclonal antibodies are commonly used in lateral flow immunochromatographic assays for drugs of abuse detection [27]. The choice between monoclonal and polyclonal antibodies affects assay specificity and lot-to-lot consistency. Monoclonal antibodies provide defined specificity but require hybridoma development, while polyclonal antibodies are easier to produce but may vary between batches [27].

Buffer Composition

The composition of buffers used in the conjugate pad, sample pad, and membrane blocking steps affects assay performance. Buffers control the pH and ionic strength of the sample as it flows through the strip, which influences binding reactions and nonspecific interactions [8].

Blocking buffers are used to reduce nonspecific binding of sample components to the membrane and reagents. The blocking agent must be compatible with the detection chemistry and must not interfere with the binding of the analyte to the capture and detection reagents [8].

Drying and Storage Conditions

The drying conditions for the conjugate pad and the storage conditions for the assembled strips affect reagent stability and assay performance. Drying must preserve the activity of the biological reagents while ensuring efficient release on rehydration [8].

Reagent lyophilization can minimize cold chain dependence for deployable diagnostics [17]. Lyophilized reagents are stable at ambient temperatures, which simplifies distribution and storage in resource-limited settings [17].

Computational Modeling in Assay Design

Computational modeling offers a framework for predicting lateral flow assay performance and guiding design decisions [6]. Models can simulate the flow of sample through the strip, the binding reactions at the test and control lines, and the effects of reagent concentrations and membrane properties on signal generation [6].

The integration of computational design with lateral flow development offers a promising framework to choose from an increasing number of novel materials, techniques, and reagents [6]. However, the criteria for quantifying performance and validating predictive power are critical as theory is integrated into computational models and becomes testable [6].

Practical Workflow for Developing a Lateral Flow Assay

Step 1: Define the Assay Requirements

Define the analyte, sample type, detection range, and performance requirements before beginning development. Consider the intended use setting, the available equipment, and the skill level of the end users. These requirements determine the assay format, label type, and readout method [8].

Step 2: Select the Assay Format

Choose between sandwich and competitive formats based on the size and properties of the analyte. Sandwich formats are appropriate for large analytes with multiple binding sites, while competitive formats are used for small molecules [8]. Consider whether nucleic acid detection is required and whether amplification is necessary [11].

Step 3: Select and Characterize Binding Reagents

Select antibodies, aptamers, or nucleic acid probes with appropriate affinity and specificity for the target. Characterize the binding reagents for their performance in the lateral flow format, including their stability under drying and storage conditions [8].

Step 4: Select the Label and Conjugation Chemistry

Choose the label type based on the required sensitivity and the available readout equipment. Gold nanoparticles provide visual detection without equipment, while fluorescent labels require a reader but offer higher sensitivity [8]. Optimize the conjugation chemistry to ensure stable and functional labeled reagents [12].

Step 5: Select Membrane and Pad Materials

Evaluate different membrane types and pore sizes for their flow characteristics and protein binding capacity. Select sample pad and conjugate pad materials that are compatible with the sample type and provide efficient reagent release [8].

Step 6: Optimize Reagent Concentrations

Optimize the concentrations of the labeled detection reagent, the capture reagent at the test line, and the control reagent. The optimal concentrations balance signal intensity against nonspecific binding and reagent cost [8].

Step 7: Assemble and Test Prototype Strips

Assemble prototype strips and test them with known positive and negative samples. Evaluate the limit of detection, sensitivity, specificity, and reproducibility of the assay. Use the results to refine the design parameters [8].

Step 8: Validate the Assay Performance

Validate the assay with a panel of well-characterized samples that represent the intended use population. Establish the limit of detection, dynamic range, and precision of the assay. Compare the performance with reference methods where available [4].

Records and Measurements

Documentation Requirements

Maintain detailed records of all development activities, including reagent lots, buffer compositions, membrane lots, and test results. Documentation supports troubleshooting, lot-to-lot consistency, and regulatory submissions [1].

Quality management systems provide a framework for documenting and controlling laboratory processes [1]. The World Health Organization Laboratory Quality Management System Handbook describes the requirements for a comprehensive quality management system in a laboratory setting [1].

Performance Metrics

The limit of detection is the lowest concentration of analyte that can be reliably distinguished from a blank sample. The limit of detection depends on the label type, the affinity of the binding reagents, and the flow characteristics of the membrane [8].

Sensitivity and specificity describe the ability of the assay to correctly identify positive and negative samples. A duplex recombinase-aided amplification lateral flow dipstick assay for distinguishing Mycobacterium tuberculosis and Mycobacterium avium complex demonstrated a sensitivity of 92.86 percent and a specificity of 93.75 percent using Xpert/MTB RIF as the gold standard [20].

Quality Control Records

Quality control records document the performance of each lot of lateral flow strips. Control samples with known analyte concentrations are tested to verify that the assay meets its performance specifications. The results of quality control testing are recorded and reviewed before the lot is released for use [1].

Common Failure Patterns and Troubleshooting

Weak or Absent Test Line

A weak or absent test line in the presence of a valid control line indicates that the assay failed to detect the analyte. Possible causes include insufficient analyte in the sample, degraded detection reagents, suboptimal capture reagent concentration, or incomplete release of the labeled reagent from the conjugate pad [8].

Weak or Absent Control Line

A weak or absent control line indicates that the liquid did not flow through the strip or that the detection reagents did not function. Possible causes include a blocked sample pad, dried reagents that failed to release, or a defective membrane [8].

High Background Signal

High background signal reduces the contrast between the test line and the surrounding membrane, making results difficult to interpret. Possible causes include nonspecific binding of the labeled reagent to the membrane, inadequate blocking, or excessive labeled reagent concentration [8].

Steric Hindrance and Competitive Binding

The use of multiple biotinylated molecules in a single assay can lead to assay failure due to competitive binding and steric hindrance [15]. Excess biotin on multiple components competes for streptavidin binding sites, causes improper binding configurations, disrupts protein folding, and interferes with biotin-streptavidin interactions [15]. Using two different molecules for immobilization and signal generation can prevent this failure mode [15].

Flow Disruption

Loosening of strip components can disrupt the continuity of the flow path and cause residue of the solution, decreasing detection robustness and sensitivity [16]. Integrated fabrication approaches that produce all components on a single membrane can maintain flow continuity and improve detection robustness [16].

False Positive Results

False positive results can occur when the detection reagents bind to sample components other than the target analyte. Nonspecific binding can be reduced by optimizing the blocking conditions, the reagent concentrations, and the wash steps [8].

Safety and Regulatory Context

Biosafety Considerations

Laboratory work with biological samples and reagents requires adherence to biosafety guidelines. The World Health Organization Laboratory Biosafety Manual provides guidance for the safe handling of biological materials in the laboratory [2].

Lateral flow assay development may involve the use of pathogenic microorganisms or clinical samples. Work with these materials must be conducted in accordance with the appropriate biosafety level and containment practices [2]. Personal protective equipment, proper waste disposal, and decontamination procedures are essential components of a safe laboratory environment [2].

Regulatory Requirements for Diagnostic Devices

Lateral flow assays intended for clinical diagnostic use are subject to regulatory requirements that vary by jurisdiction. The U.S. Food and Drug Administration Bioanalytical Method Validation Guidance describes the expectations for validation of bioanalytical methods used to support regulatory submissions [4].

The National Center for Advancing Translational Sciences Assay Guidance Manual provides recommendations for assay development and validation in the context of drug discovery and translational research [3]. The manual covers assay design, optimization, and qualification for a range of assay formats [3].

Professional Escalation Criteria

Laboratory personnel should escalate issues to a supervisor or qualified professional when they encounter unexpected results, reagent failures, or safety concerns. Escalation is appropriate when troubleshooting efforts do not resolve the issue, when assay performance falls outside established acceptance criteria, or when there is any question about the validity of results [1].

Limitations of Lateral Flow Assays

Sensitivity Limitations

Lateral flow assays generally have lower sensitivity than laboratory-based methods such as enzyme-linked immunosorbent assays or polymerase chain reaction. The sensitivity depends on the label type, the affinity of the binding reagents, and the flow characteristics of the membrane [8].

Signal amplification strategies can improve the sensitivity of lateral flow assays. The incorporation of advanced technologies including DNA probes, nucleic acid enzymes, aptamers, and antigen-antibody binding has significantly improved the sensitivity and specificity of lateral flow assays for heavy metal ion detection [24].

Quantitative Limitations

Most lateral flow assays provide qualitative or semi-quantitative results. The signal intensity at the test line can be correlated with analyte concentration, but the precision of this correlation is limited compared with laboratory-based quantitative methods [8].

Reader devices can improve the quantitative performance of lateral flow assays by measuring the signal intensity at the test line. Fluorescent labels require a reader for signal detection but offer higher sensitivity and more precise quantification than visual readout [14].

Matrix Effects

The sample matrix can affect lateral flow assay performance through nonspecific binding, interference with the detection reaction, or physical properties such as viscosity and particulate content [8]. Matrix effects must be evaluated during assay development and validation [4].

Serum components can quench the fluorescence of certain labels. Quantum dots performed poorly in undiluted human serum due to perturbation of the zinc sulfide shell by serum components, while europium chelate-doped polystyrene nanoparticles protected the fluorophore from serum-induced quenching [14].

Stability and Shelf-Life

The stability of lateral flow assays depends on the reagents, the drying conditions, and the storage environment. Biological reagents such as antibodies and enzymes can lose activity over time, particularly at elevated temperatures and humidity [8].

Reagent lyophilization can improve stability and minimize cold chain dependence for deployable diagnostics [17]. Lyophilized reagents are stable at ambient temperatures, which simplifies distribution and storage in resource-limited settings [17].

Frequently Asked Questions

What is the function of the conjugate pad in a lateral flow assay?

The conjugate pad stores the dried detection reagent, typically a labeled antibody, aptamer, or nucleic acid probe. When the sample flows through the pad, the dried reagent is rehydrated and released into the sample stream. The release efficiency of the conjugate pad affects the amount of labeled reagent available for binding and therefore the assay sensitivity [8].

How does the nitrocellulose membrane affect lateral flow assay performance?

The nitrocellulose membrane provides the surface where capture reagents are immobilized and where the signal is generated. Membrane pore size affects the flow rate of the sample, which influences the time available for binding reactions and the sensitivity of the assay. Different membrane types can perform similarly in some nucleic acid lateral flow formats [11].

What is the difference between sandwich and competitive lateral flow assays?

Sandwich assays are used for analytes large enough to bind two antibodies or other binding reagents simultaneously. The analyte forms a bridge between a labeled detection reagent and an immobilized capture reagent, producing a signal that increases with analyte concentration. Competitive assays are used for small molecules that cannot bind two antibodies, where the analyte competes with an immobilized analog for binding to a limited amount of labeled reagent [14].

What labels can be used for signal detection in lateral flow assays?

Gold nanoparticles are the most common label because they produce a visible red signal without additional development steps. Fluorescent labels such as quantum dots and europium chelate-doped nanoparticles offer higher sensitivity but require a reader device. Surface-enhanced Raman scattering labels provide another approach for sensitive detection [9][14].

How are nucleic acid targets detected in lateral flow assays?

Nucleic acid targets are typically amplified before detection, often by isothermal methods such as recombinase-aided amplification or loop-mediated isothermal amplification. The amplified products are detected by hybridization to labeled probes and capture probes immobilized on the membrane. CRISPR-based detection systems can also be combined with lateral flow readout [11][19][20].

What causes a weak or absent control line in a lateral flow assay?

A weak or absent control line indicates that the liquid did not flow through the strip or that the detection reagents did not function. Possible causes include a blocked sample pad, dried reagents that failed to release, or a defective membrane. A test result is invalid if the control line does not appear [8].

Can lateral flow assays detect multiple analytes simultaneously?

Yes, multiplex lateral flow assays detect multiple analytes by incorporating multiple test lines on a single membrane. Each test line contains a capture reagent specific for a different analyte. Multiplex formats have been developed for inflammatory biomarkers and for distinguishing closely related pathogens [16][20].

What are the main limitations of lateral flow assays?

Lateral flow assays generally have lower sensitivity than laboratory-based methods and most provide qualitative or semi-quantitative results. The sample matrix can interfere with detection, and the stability of biological reagents can limit shelf-life. Signal amplification strategies and reader devices can address some of these limitations [8][24].

Related Diagnostic Guides

• CRISPR Cas12a Based Lateral Flow Assay for Rapid Point of Care Detection of African Swine Fever Virus in Porcine Blood and Oral Fluids
• BCA Assay Protocol: Principles and Step-by-Step Instructions
• Immunofluorescence Assay: Principles and Protocol for Protein Localization
• Affinity Chromatography for Protein Purification: Principles and Column Selection
• Enzyme Activity Assay: Principles and Protocol for Measuring Catalytic Activity

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• Improving Lateral Flow Assay Performance Using Computational Modeling.. Annual review of analytical chemistry (Palo Alto, Calif.), 2018.
• Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine.. Cureus, 2024.
• Tutorial: design and fabrication of nanoparticle-based lateral-flow immunoassays.. Nature protocols, 2020.
• CRISPR/Cas13a-driven lateral flow assay for preamplification-free and ultrasensitive miRNA-21 detection.. Biosensors & bioelectronics, 2025.
• Lateral flow assay-based detection of long non-coding RNAs: A point-of-care platform for cancer diagnosis.. Journal of pharmaceutical and biomedical analysis, 2021.
• Design of a lateral flow assay targeting the conserved NIID_2019-nCoV_N gene region for molecular viral diagnosis.. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2025.
• Design and optimizing gold nanoparticle-cDNA nanoprobes for aptamer-based lateral flow assay: Application to rapid detection of acetamiprid.. Biosensors & bioelectronics, 2022.
• Point-of-care COVID-19 diagnostics powered by lateral flow assay.. Trends in analytical chemistry : TRAC, 2021.
• Ultrasensitive de novo Protein Sandwich Lateral flow Fluorescence Assay for Cortisol in Saliva and Serum using Quantum dots and Europium Nanoparticles.. 2026.
• Probable hindrance of visible colour due to excess biotin with CRISPR-dCas9-sgRNA lateral flow assay detection of HPV16 and HPV18: a negative finding.. 2026.
• Unidirectional-flow assay strip fabricated via an integrated process for multiplex detection of inflammatory biomarkers.. 2026.
• Towards deployable CRISPR-based nucleic acid detection.. 2026.
• Molecularly Imprinted Polymers as Biomimetic Test Zones in Paper-Based Nucleic Acid Assays-Comparing Vertical and Lateral Flow Formats.. 2026.
• A CRISPR-Cas13a-based two-step assay combined with lateral flow strips for rapid detection of Epstein-Barr virus.. 2026.
• Duplex recombinase aided amplification-lateral flow dipstick assay for rapid distinction of Mycobacterium tuberculosis and Mycobacterium avium complex. Frontiers in Cellular and Infection Microbiology, 2024.
• Lateral flow assays for viruses diagnosis: Up-to-date technology and future prospects. Trends in Analytical Chemistry (TrAC), 2022.
• Design principles for LAMP-CRISPR molecular diagnostics.. Methods, 2026.
• Recent developments of aptamer-based lateral flow assays for point-of-care (POC) diagnostics.. Analytical Biochemistry, 2022.
• Heavy Metal Ion Detection Based on Lateral Flow Assay Technology: Principles and Applications. Biosensors, 2025.
• Lateral flow assays: Principles, designs and labels. Trac Trends in Analytical Chemistry, 2016.
• Rapid prototyping of lateral flow assays.. Methods in Molecular Biology Clifton N J, 2009.
• Monoclonal antibodies application in lateral flow immunochromatographic assays for drugs of abuse detection. Molecules, 2021.
• Advances in the research of lateral flow assays applied in detecting disease biomarkers. Chinese Journal of Laboratory Medicine, 2024.

This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.